Novo Nordisk reports 2023 sales up 36% at constant exchange rates to DKK 232.3B

Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3B in 2023. Operating profit increased by 37% in Danish kroner and by 44% at constant exchange rates, or CER, to DKK 102.6B. At the Annual General Meeting on 21 March 2024, the Board of Directors will propose a final dividend of DKK 6.40 for 2023 per share. The expected total dividend for 2023 is DKK 9.40 per share, of which DKK 3.00 was paid as interim dividend in August 2023. The Board of Directors has decided to initiate a new share repurchase program of up to DKK 20B. Lars Fruergaard Jorgensen, president and CEO: “We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments. We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity.”